Skip to main content
Matthew Laughon, MD, Neonat/Perinatology, Chapel Hill, NC

Matthew M Laughon MD


Professor, Pediatrics, The University of North Carolina at Chapel Hill

Join to view full profile
  • 101 Manning DrChapel Hill, NC 27514

  • Phone+1 984-974-1000

  • Fax+1 919-966-7772

Dr. Laughon is on Doximity

As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.

  • Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
  • Connect with colleagues in the same hospital or clinic.
  • Read the latest clinical news, personalized to your specialty.

Education & Training

  • University of North Carolina Hospitals
    University of North Carolina HospitalsFellowship, Neonatal-Perinatal Medicine, 2001 - 2004
  • University of North Carolina at Chapel Hill
    University of North Carolina at Chapel HillMPH, Epidemiology, 2004
  • University of North Carolina Hospitals
    University of North Carolina HospitalsResidency, Pediatrics, 1998 - 2001
  • University of Virginia School of Medicine
    University of Virginia School of MedicineClass of 1998
  • Davidson College
    Davidson CollegeB.S., Magna Cum Laude, 1994

Certifications & Licensure

  • NC State Medical License
    NC State Medical License 1999 - 2027
  • Neonatal-Perinatal Medicine
    American Board of Pediatrics Neonatal-Perinatal Medicine

Awards, Honors, & Recognition

  • K30 Scholar-Clinical Research Curriculum NIH, 2003
  • Phi Beta Kappa 1993
  • Samuel H. Bell Honor Scholar Davidson College, 1990

Clinical Trials

Publications & Presentations

PubMed

Journal Articles

  • Agreement of an Echocardiogram-Based Diagnosis of Pulmonary Hypertension in Infants at Risk for Bronchopulmonary Dysplasia Among Masked Reviewers  
    Rachel D Torok, Matthew M Laughon, Andrew W McCrary, Christoph P Hornik, Jennifer S Li, Nature
  • Characterization of the Population Pharmacokinetics of Ampicillin in Neonates Using an Opportunistic Study Design  
    Tremoulet A, Le J, Poindexter B, Sullivan JE, Laughon M, Delmore P, Salgado A, Ian-U Chong S, Melloni C, Gao J, Benjamin DK Jr, Capparelli EV, Cohen-Wolkowiez M; on be..., Antimicrob Agents Chemother, 6/1/2014
  • Trends in Caffeine Use and Association between Clinical Outcomes and Timing of Therapy in Very Low Birth Weight Infants  
    Dobson NR, Patel RM, Smith PB, Kuehn DR, Clark J, Vyas-Read S, Herring A, Laughon MM, Carlton D, Hunt CE, J Pediatr, 5/1/2014

Books/Book Chapters

Abstracts/Posters

  • Sedatives and Analgesics Given To Dying Infants in Neonatal Intensive Care Units.
    Zimmerman KO, Hornik CP, Watt KM, Clark RH, Laughon MM, Smith PB, PAS, 1/1/2014
  • Analysis of the BPCA Priority List: Are Drug Priorities Reflective of Clinical Need in Hospitalized Infants?
    Gostelow M, Tripathi N, Benjamin Jr DB, Hornik CP, Cohen-Wolkowiez M, Clark R, Laughon MM, Smith PB, PAS, 1/1/2014
  • Batton B, Li L, Newman N, Das A, Watterberg K, Yoder B, Faix R, Laughon M, Stoll B, Higgins R, PAS, 1/1/2014

Other

  • Dissemination of Information from Pediatric Studies Conducted under BPCA and PREA. 
    Smith PB, Laughon MM, National Academies of Science Institute of Medicine, Appendix B
    1/1/2013

Press Mentions

  • UNC Study Confirms Early Use of Medications May Lead to Life-Threatening Conditions in Preterm Infants with Heart Defect
    UNC Study Confirms Early Use of Medications May Lead to Life-Threatening Conditions in Preterm Infants with Heart DefectDecember 9th, 2025
  • Prolonged Duration of Early Antibiotic Therapy in Extremely Premature Infants
    Prolonged Duration of Early Antibiotic Therapy in Extremely Premature InfantsJune 1st, 2019
  • Neurodevelopmental Outcomes Among Extremely Premature Infants with Linear Growth Restriction
    Neurodevelopmental Outcomes Among Extremely Premature Infants with Linear Growth RestrictionOctober 23rd, 2018

Grant Support

  • North Carolina Clinical CenterDUKE UNIVERSITY2001–2030
  • PRISMDUKE UNIVERSITY2023–2028
  • PRISMDUKE UNIVERSITY2023–2028
  • Safety of Sildenafil in Premature Infants with Severe Bronchopulmonary DysplasiaDUKE UNIVERSITY2019–2025
  • Safety of Sildenafil in Premature Infants at Risk of Bronchopulmonary DysplasiaUNIV OF NORTH CAROLINA CHAPEL HILL2018–2025

Viewing the full profile is available to verified healthcare professionals only.

Find your profile and take control of your online presence: